Investment Stage – Series A & B
Definigen produces hIPSC derived hepatocytes, pancreatic beta cells and lung endothelial cells for use in drug discovery and toxicology testing for the biotech and pharma industry.
Spex Capital Ltd is an appointed representative of J8 Capital Management LLP which is authorised and regulated by the Financial Conduct Authority.
©2022 · Spex Capital
©2021 · Spex Capital